Skip to main content
SpringerLink
Log in

Immunoglobulin Treatment for Primary Antibody Deficiencies

Advantages of the Subcutaneous Route

  • Therapy Review
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Adults and children with primary antibody deficiencies are prone to bacterial infections affecting the respiratory tract and gastrointestinal canal. To prevent or alleviate infections, replacement therapy with IgG is needed, usually on a lifelong basis. The IgG can be administered intramuscularly, intravenously, or subcutaneously. Subcutaneous IgG (SCIG) therapy, using small portable pumps for once-per-week self infusions, has shown many advantages compared with the two other routes of administration. This review highlights findings from international studies and demonstrates that: (i) SCIG therapy is safe, with very few adverse effects; (ii) the therapy can be used for patients with previous adverse effects to intravenous administration of IgG; (iii) the therapy leads to high serum IgG levels and good protection against infections; (iv) the therapy facilitates home therapy, as the infusion technique is easy for children, adults and elderly people to learn and there is no need for venous access; (v) SCIG home therapy leads to significantly improved life situations for the patients; (vi) the SCIG home therapy regimen in particular reduces the costs of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Fig. 3
Table II
Fig. 4
Fig. 5
Fig. 6
Table III

Similar content being viewed by others

References

  1. Chapel HM. Consensus Panel for the Diagnosis and Management of Primary Antibody Deficiencies. Consensus on diagnosis and management of primary antibody deficiencies. BMJ 1994; 308: 581–5

    Article  PubMed  CAS  Google Scholar 

  2. Rosen FS, Eibl M, Roifman C, et al. Primary immunodeficiency diseases. Report of an IUIS Scientific Committee. Clin Exp Immunol 1999; 118Suppl. 1: 1–28

    Google Scholar 

  3. Notarangelo L, Cassanova JL, Fischer A, et al. Primary immunodeficiency diseases: an update. J Allergy Clin Immunol 2004; 114: 667–87

    Article  Google Scholar 

  4. Bruton OC. Agammaglobulinemia. Pediatrics 1952; 9: 722–8

    PubMed  CAS  Google Scholar 

  5. Berger M, Cupps TR, Fauci AS. Immunoglobulin replacement therapy by slow subcutaneous infusions. Ann Intern Med 1980; 93: 55–6

    PubMed  CAS  Google Scholar 

  6. Gardulf A. Rapid subcutaneous immunoglobulin replacement therapy in patients with primary antibody deficiency: aspects of effectiveness, safety, home therapy, quality of life and costs. Stockholm: Karolinska Institute, 1994

    Google Scholar 

  7. Gardulf A, Hammmarström L. Subcutaneous administration of immunoglobulins: what are the advantages? Clin Immunother 1996; 6: 108–16

    Article  Google Scholar 

  8. Van der Meer JWM, van Furth R, Roord JJ. Subcutaneous administration of gammaglobulin. In: Nydegger UE, editor. Immunotherapy: a guide to immunoglobulin prophylxix and therapy. London: Academic Press, 1981: 133–42

    Google Scholar 

  9. Gardulf A, Hammarström L, Smith CIE. Home treatment of hypogammaglobu-linemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991; 338: 162–6

    Article  PubMed  CAS  Google Scholar 

  10. Hansen S, Gustafson R, Smith CIE, et al. Subcutaneous IgG infusions in patients with primary antibody deficiencies: decreased time of delivery with maintained safety. Clin Immunol 2002; 104: 237–41

    Article  PubMed  CAS  Google Scholar 

  11. Gardulf A, Björvell H, Gustafson R, et al. Safety of rapid subcutaneous gammaglobulin infusions in patients with primary antibody deficiency. Immunodeficiency 1993; 4: 81–4

    PubMed  CAS  Google Scholar 

  12. Thomas MJ, Brennan VM, Chapel HM. Rapid subcutaneous immunoglobulin infusions in children. Lancet 1993; 342: 1432–3

    Article  PubMed  CAS  Google Scholar 

  13. Gardulf A, Andersen V, Björkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995; 345: 365–9

    Article  PubMed  CAS  Google Scholar 

  14. Abrahamsen TG, Sandersen H, Bustnes A. Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics 1996; 98: 1127–31

    PubMed  CAS  Google Scholar 

  15. Gustafson R, Gardulf A, Granert C, et al. Prophylactic therapy for selective IgA deficiency. Lancet 1997; 350: 865

    Article  PubMed  CAS  Google Scholar 

  16. Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement therapy by rapid subcutaneous infusions. Arch Dis Child 1998; 79: 48–51

    Article  PubMed  CAS  Google Scholar 

  17. Chapel HM, Spickett GP, Ericson D, et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000; 20: 94–100

    Article  PubMed  CAS  Google Scholar 

  18. Andersen V, Franke K, Erkel J, et al. Subkutane IgG-infusion bei patients mit primärem immundefekt: eine retrospektive fallsammlung. Mitt Bayer Ges Immun-Tropenmed Impfwesen 2001: 14-7

  19. Radinsky S, Bonagura VR. Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin. J Allergy Clin Immunol 2003; 112: 630–3

    Article  PubMed  CAS  Google Scholar 

  20. Eijkhout HW, van der Broek PJ, van der Meer JWM. Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe reactions to previous immunoglobulin therapy. Neth J Med 2003; 61: 213–7

    PubMed  CAS  Google Scholar 

  21. Berger M, Duff K, Poll J, et al. IgG replacement by the subcutaneous route using preparations licensed in the US for administration by other routes. In: Dalakas MS, Späth PJ, editors. Intravenous immunoglobulins in the third millennium. Proceedings of the 5th International Symposium on IVIG. New York: The Parthenon Publishing Group, 2004: 77–80

    Google Scholar 

  22. Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies: a prospective, multi-national study. J Clin Immunol 2006; 26: 177–85

    Article  PubMed  CAS  Google Scholar 

  23. Ochs HD, Gupta S, Kiessling P, et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006; 26: 265–73

    Article  PubMed  CAS  Google Scholar 

  24. Gardulf A, Hansen S, Johansson K, et al. Rapid subcutaneous IgG replacement therapy in children and adults: 20 years of clinical experience. Immunologia 2006; 24: 50–3

    Google Scholar 

  25. Ochs HD, Fischer SH, Wedgwood RJ, et al. Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases. Am J Med 1984; 76: 78–82

    Article  PubMed  CAS  Google Scholar 

  26. Bonilla FA, Geha RS. Update on primary immunodeficiency diseases. J Allergy Clin Immunol 2006; 117 (2 Suppl. Mini-Primer): S435–41

    Article  PubMed  CAS  Google Scholar 

  27. Gustafson R, Hammarström L, Leibl H, et al. Pharmacokinetics and safety of Gammabulin S/D [abstract and poster P02-29]. 9th Meeting of the European Society for Immunodeficiencies; 2000 Nov 5–9; Geneva

  28. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 2004; 112: 1–7

    Article  PubMed  CAS  Google Scholar 

  29. Dams ETM, van der Meer JWM. Subcutaneous immunoglobulin replacement therapy in patients with primary antibody deficiencies. Lancet 1995; 345: 864

    Article  PubMed  CAS  Google Scholar 

  30. Waniewski J, Gardulf A, Hammarström L. Bioavailability of gammaglobulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol 1994; 14: 90–7

    Article  PubMed  CAS  Google Scholar 

  31. Ugazsio AG, Duse M, Re R, et al. Subcutaneous infusion of gammaglobulins in management of agammaglobulinemia. Lancet 1982; I: 226

    Article  Google Scholar 

  32. Björkander J, Bengtsson U, Oxelius V-A, et al. Symptoms in patients with lowered levels of IgG subclasses, with or without IgA deficiency, and effects of immunoglobulin prophylaxis. Monogr Allergy 1986; 20: 157–63

    PubMed  Google Scholar 

  33. Thampakkul S, Ballow M. Replacement intravenous immune serum globulin therapy in patients with antibody immune deficiency. Immunol Allergy Clin North Am 2001; 21: 165–84

    Article  Google Scholar 

  34. Gustafson R, Hammarström L. Subcutaneous immunoglobulin replacement therapy. Ellipse 2002; 18: 45–8

    Google Scholar 

  35. Wells JV. Metabolism of immunoglobulins. In: Fudenberg HH, Stites DP, Cald-well JL, et al., editors. Basic and clinical immunology. 2nd ed. Los Altos (CA): Lange Medical Publishing, 1978: 237–45

    Google Scholar 

  36. Ochs HD, Smith CIE. X-linked agammaglobulinemia: a clinical and molecular analysis. Medicine 1996; 75: 287–99

    Article  PubMed  CAS  Google Scholar 

  37. Gardulf A, Björvell H, Gustafson R, et al. The life situation of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clin Exp Immunol 1993; 92: 200–4

    Article  PubMed  CAS  Google Scholar 

  38. Gardulf A, Nicolay U, Asensio O, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004; 114: 936–42

    Article  PubMed  CAS  Google Scholar 

  39. Nicolay U, Kiessling P, Berger M, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 2006; 26: 65–72

    Article  PubMed  CAS  Google Scholar 

  40. Fayers PM, Sprangers MAG. Understanding self-rated health. Lancet 2002; 359: 187–8

    Article  PubMed  Google Scholar 

  41. Spertus JA, Jones P, McDonell M, et al. Health predicts long-term outcome in outpatients with coronary disease. Circulation 2002; 106: 43–9

    Article  PubMed  Google Scholar 

  42. Bailis DS, Segall A, Chipperfield JG. Two views of self-rated health status. Soc Sci Med 2003; 56: 203–17

    Article  PubMed  Google Scholar 

  43. Manderbacka K, Kåreholt I, Martikainen P, et al. The effect of point of reference on the association between self-rated health and mortality. Soc Sci Med 2003; 56: 1447–52

    Article  PubMed  Google Scholar 

  44. Gardulf A, Andersson E, Lindqvist M, et al. Rapid subcutaneous IgG replacement therapy at home for pregnant immunodeficient women. J Clin Immunol 2001; 21: 150–4

    Article  PubMed  CAS  Google Scholar 

  45. Hansen S, Gardulf A, Andersson E, et al. Women with primary antibody deficiencies requiring IgG replacement therapy: their perception of prenatal care during pregnancy. J Obstet Gynecol Neonatal Nurs 2004; 33: 604–9

    Article  PubMed  Google Scholar 

  46. Gardulf A, Björvell H, Andersen V, et al. Lifelong treatment with gammaglobulin to patients with primary antibody deficiencies: the patients’ experiences of subcutaneous self-infusions and home therapy. J Adv Nurs 1995; 21: 917–27

    Article  PubMed  CAS  Google Scholar 

  47. Kittner JM, Grimbacher B, Wulff W, et al. Patients’ attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol 2006; 26: 400–5

    Article  PubMed  CAS  Google Scholar 

  48. Gardulf A, Gustafson R. Substitutionsbehandling med gammaglobulin vid antikroppsbrist. In: Jönsson G, editor. Boken om immunbrist. Primära och sekundära orsaker till nedsatt immunitet. Uddevalla (Sweden): DMF, 2003: 20

    Google Scholar 

  49. Berger M. A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies. Curr Allergy Asthma Report 2002; 2: 368–78

    Article  Google Scholar 

  50. Cunningham-Rundles C, Zhou Z, Mankarious S, et al. Long-term use of IgA depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies. J Clin Immunol 1993; 13: 272–8

    Article  PubMed  CAS  Google Scholar 

  51. Sundin U, Nava S, Hammarström L. Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol 1998; 112: 341–6

    Article  PubMed  CAS  Google Scholar 

  52. Nicolay U. Health-related quality of life, treatment satisfaction and clinical aspects of patients with primary antibody deficiencies receiving subcutaneous IgG self-infusions at home. Stockholm: Karolinska Institute, 2006

    Google Scholar 

  53. Borte M, Oertelt C, Högy B. Behandlung von Patienten mit primären Antikörpermangelsyndromen in Deutschland. Klin Pädiatr 2005; 217: 276–80

    Article  PubMed  CAS  Google Scholar 

  54. Daly PB, Evans JH, Kobayashi RH, et al. Home-based immunoglobulin infusion therapy: quality of life and patient health perceptions. Ann Allergy 1991; 67: 504–10

    PubMed  CAS  Google Scholar 

  55. Gardulf A, Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol 2006; 6: 1–9

    Article  Google Scholar 

  56. Høybraten Sigstad HM, Stray-Pedersen A, Frøland SS. Coping, quality of life, and hope in adults with primary antibody deficiencies. Health Qual Life Outcomes 2005; 3: 31

    Article  Google Scholar 

  57. Lorig K. Patient education. A practical approach. 3rd ed. Thousand Oaks (CA): Sage Publications, Inc., 2001

    Google Scholar 

  58. Rankin SH, Stallings KD. Patient education. Principles and practice. 4th ed. Philadelphia (PA): Lippincott, 2001

    Google Scholar 

  59. Högy B, Keinecke H-O, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health Econom 2005; 50: 24–9

    Article  Google Scholar 

  60. Gardulf A, Möller G, Jonsson E. A comparison of the patient-borne costs of therapy with gammaglobulin given at the hospital or at home. Int J Technol Assess Health Care 1995; 11: 345–53

    Article  PubMed  CAS  Google Scholar 

  61. Olinder-Nielsen A-M, Granert C, Forsberg P, et al. Immunoglobulin prophylaxis in 350 adults with IgG subclass deficiency and recurrent respiratory tract infections: a long term follow-up. Scand J Inf Dis 2007; 39: 44–50

    Article  CAS  Google Scholar 

  62. Hammarström L, Samuelsson J, Grimfors G. Subcutaneous gammaglobulin for patients with secondary hypogammaglobulinaemia. Lancet 1995; 345: 382–3

    PubMed  Google Scholar 

  63. Yu Z, Lennon VA. Mechanisms of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. New Engl J Med 1999; 340: 227–8

    Article  PubMed  CAS  Google Scholar 

  64. Elkayam O, Paran D, Milo R, et al. Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders: a study of four cases. Ann Rheum Dis 2000; 59: 77–80

    Article  PubMed  CAS  Google Scholar 

  65. Alliot C, Rapin JP, Besson M, et al. Pulmonary embolism after intravenous immunoglobulin. J R Soc Med 2001; 94: 187–8

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The author is grateful to Hilary Hocking from (Östersund, Sweden, for language revision. The review work was supported by grants from Stockholm County Council (medical ALF project grant), Stockholm, Sweden, and by Karolinska Institutet, Stockholm, Sweden, via research funds. The author has no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine, Section of Clinical Immunology, F79, Karolinska Institutet at Karolinska University Hospital, Huddinge, Stockholm, SE-141 86, Sweden

    Ann Gardulf

Authors
  1. Ann Gardulf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ann Gardulf.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gardulf, A. Immunoglobulin Treatment for Primary Antibody Deficiencies. BioDrugs 21, 105–116 (2007). https://doi.org/10.2165/00063030-200721020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200721020-00005

Keywords

Search

Navigation